Steven Remer, MD
Pain Medicine · Allen, TXNPI 1447261573
Payments from drug & device makers
Across 216 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- AbbVie$229
- Stimwave Technologies Incorporated$180
- Scilex Pharmaceuticals Inc.$165
- Pfizer$141
- Abbott$129
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,371100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 113 | $1,138 |
| AbbVie(2 entities) | 11 | $229 |
| Stimwave Technologies Incorporated | 1 | $180 |
| Scilex Pharmaceuticals Inc. | 10 | $165 |
| Pfizer | 8 | $141 |
| Abbott | 5 | $129 |
| Arbor Pharmaceuticals, Inc. | 8 | $127 |
| Medtronic(2 entities) | 5 | $115 |
| Novartis | 5 | $103 |
| Biohaven Pharmaceuticals, Inc. | 5 | $103 |
| Lundbeck LLC | 4 | $91 |
| Pacira Therapeutics, Inc. | 4 | $84 |
| Forte Bio-pharma LLC | 2 | $79 |
| VGI Medical, LLC | 1 | $70 |
| Boston Scientific | 4 | $66 |
| Azurity Pharmaceuticals, Inc. | 4 | $66 |
| Johnson & Johnson | 3 | $53 |
| Biodelivery Sciences International, Inc. | 4 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Vertex | 1 | $27 |
| Trevena, Inc. | 1 | $26 |
| Nevro Corp. | 1 | $26 |
| Bioventus LLC | 1 | $25 |
| Painteq LLC | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Si-bone, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| SPR Therapeutics, Inc | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Nalu Medical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$3,371 in reported general payments places this provider in the 50th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 25 | $32,036 |
| Xtampza ErOxycodone Myristate | 50 | $28,926 |
| OxycontinOxycodone Hcl | 24 | $26,649 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 560 | $17,734 |
| Nucynta ErTapentadol Hcl | 12 | $13,832 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 259 | $8,450 |
| Morphine Sulfate ErMorphine Sulfate | 168 | $5,557 |
| Oxycodone Hcl | 186 | $4,547 |
| Gabapentin | 315 | $3,418 |
| Lidocaine | 23 | $2,861 |
| Methocarbamol | 106 | $1,810 |
| Fentanyl | 14 | $1,357 |
| Tizanidine Hcl | 169 | $1,254 |
| Tramadol Hcl ErTramadol Hcl | 11 | $1,109 |
| Pregabalin | 60 | $1,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Nucynta Er | $1,138 | $74,79587 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Allen
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Muhammad ZulqarnainDallas$556K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
- David LeimanHouston$281K
- Candice BurnetteSugar Land$265K
- Ellen LinSan Antonio$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.